Recent developments have resulted in an increase of the workload borne by the public company audit committee. Those developments include new issuer obligations as a result of Section 404 of the Sarbanes-Oxley Act; continuing restatements, fraud, errors, internal investigations and SEC enforcement proceedings; ongoing onslaught of new and complex accounting and financial reporting pronouncements; auditor independence rules; and, review and approval of related person transactions. The audit committee may now find itself filling a litany of new roles, including investigator, arbiter and advisor as to diagnosis and remediation of company problems, corporate monitor, and primary liaison with the SEC and other government organizations.
Read the complete article by clicking the link below.
Read the complete article by clicking the link below.
Author(s)
Related Insights
20 December 2024
Health Care Law Today
GLP-1 Drugs: FDA “Re-Confirms” Decision Removing Tirzepatide from the Drug Shortage List
On December 19, 2024, the U.S. Food and Drug Administration (FDA) issued a Declaratory Order reevaluating and re-confirming that the tirzepatide drug shortage has been resolved. This order revoked and replaced FDA’s October 2, 2024, decision on tirzepatide.
20 December 2024
Manufacturing Industry Advisor
Christmas Came Early: Justice Delivered in Supplier Dispute Over Unjust Enrichment
The AirBoss saga continues… This holiday season, AirBoss Flexible Products Co. received a monumental legal victory, righting a costly wrong in MSSC, Inc. v. AirBoss.
19 December 2024
Health Care Law Today
HIPAA Reproductive Health Care Amendments: Compliance in an Uncertain Enforcement Landscape
The amendments to the HIPAA Privacy Rule designed to protect reproductive health care information are under legal challenge as the compliance date quickly approaches.